Dr. Newbold brings over 30 years of business development and alliance management experience to EDI, having led business teams in negotiating over $1.5 billion in announced pharma and biotech deals.

The journey from academic idea to therapeutic application has many inherent challenges that can keep potential breakthrough discoveries from moving forward.

Bae is principal investigator on the study titled “Biomimetic Vascular Matrix for Vascular Smooth Muscle Cell Mechanobiology and Pathology” that aims to identify potential new therapeutic targets for the treatment of cardiovascular disease.